Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXLINEAR, INCMXL · Entity 3882 | Director | May 20, 2026 | May 22, 2026 |
| MEDICINOVA INCMNOV · Entity 7011 | Director | June 23, 2026 | June 25, 2026 |
| Sonendo, Inc.SONX · Entity 9738 | Director | September 17, 2024 | September 19, 2024 |
| VivoSim Labs, INC.ONVO · Entity 8386 | Director | September 05, 2019 | September 09, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXLINEAR, INC
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,963 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 1,963 · Balance 1,963 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock. F2: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2027 or the date immediately preceding the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of MaxLinear, Inc. Common Stock.
F2: Subject to the Reporting Person's continuing as a Director (as defined in the 2010 Equity Incentive Plan) through such date, one hundred percent (100%) of the RSUs subject to the award will vest on the earlier to occur of May 1, 2027 or the date immediately preceding the next annual meeting of stockholders.
MEDICINOVA INC
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-06-22 | Direct | 44,500 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 44,500 · Balance 44,500 F1: The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company.
Sonendo, Inc.
Report date September 17, 2024 · Filed September 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,798 |
Reported balance
After 2024-09-17 transaction · row 1
1 source rowRow 1 · 2024-09-17 · Grant · Acquired 200,000 · Balance 262,798 F1: Represents an award of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2024 (the "Grant Date"). Each RSU represents a contingent right to receive one share of common stock, par value $0.001 per share of Sonendo, Inc. (the "Issuer"). The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of Restricted Stock Units ("RSUs") granted to the Reporting Person on September 17, 2024 (the "Grant Date"). Each RSU represents a contingent right to receive one share of common stock, par value $0.001 per share of Sonendo, Inc. (the "Issuer"). The RSUs vest in full on the earlier to occur of: (i) the one year anniversary of the Grant Date (ii) and the date of the 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board through the applicable vesting date.
VivoSim Labs, INC.
Report date September 05, 2019 · Filed September 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.27 · Expires 2029-09-05 | Direct | 52,000 |
Reported balance
After 2019-09-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-09-05 · Grant · Acquired 52,000 · Balance 52,000 F1: The option represents an automatic annual award granted pursuant to the Issuer's non-employee director compensation plan. The option shares vest and become exercisable in full on the earlier of (i) September 5, 2020 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The option represents an automatic annual award granted pursuant to the Issuer's non-employee director compensation plan. The option shares vest and become exercisable in full on the earlier of (i) September 5, 2020 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SEQUENOM INC
Report date September 07, 2016 · Filed September 07, 2016
Section 16 reporting ended · disclosed 2016-09-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 1
1 source rowRow 1 · 2016-09-07 · Other · Disposed 116,990 · Balance 0 F1: Includes 9,423 shares acquired 7/29/16 pursuant to the Issuer's Employee Stock Purchase Plan. F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2016-09-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2016-09-07 · Other · Disposed 50,000 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2026-01-25 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-07 · Disposition to issuer · Disposed 59,139 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2024-01-31 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-09-07 · Disposition to issuer · Disposed 36,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2026-01-25 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-09-07 · Disposition to issuer · Disposed 147,861 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-09-07 · Disposition to issuer · Disposed 1,713 · Balance 0 F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-09-07 · Disposition to issuer · Disposed 9,000 · Balance 0 F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2016-09-07 · Disposition to issuer · Disposed 7,000 · Balance 0 F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2016-09-07 · Disposition to issuer · Disposed 54,000 · Balance 0 F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2016-09-07 · Disposition to issuer · Disposed 155,000 · Balance 0 F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock. F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 9,423 shares acquired 7/29/16 pursuant to the Issuer's Employee Stock Purchase Plan.
F2: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F3: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
F4: Each restricted stock unit (the "RSUs") represents a contingent right to receive one share of the Issuer's Common Stock.
F5: These RSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such vested RSUs, converted into the right to receive a cash payment equal to $2.40 per share (without interest). In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 07, 2016 Filed Sep 7, 2016 16:25 UTC | SEQUENOM INC SQNM · Entity 182543 | OtherCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140394 · doc4.xml · nonDerivative · entry 2 BEAVER CAROLYN · CIK 0001335581 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F2 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:25 UTC | SEQUENOM INC SQNM · Entity 182543 | OtherCommon Stock | 116,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140394 · doc4.xml · nonDerivative · entry 1 BEAVER CAROLYN · CIK 0001335581 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 9,423 shares acquired 7/29/16 pursuant to the Issuer's Employee Stock Purchase Plan. F2 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.